A Hair-trigger for Cells Fighting Infection
Microscopy image showing collections of mRNA molecules, called RNA granules (green), inside B cells that are altering their genes to produce antibodies. DNA is shown in blue. Credit: Dr Manuel Díaz-Muñoz
To fight infections cells in the immune system play a dangerous game with their own genes. Damaging genes allows B cells to make antibodies that are specifically equipped to target to specific causes of illness, but damaging genes also puts them at risk of becoming cancerous. A new study led by scientists at the Babraham Institute in Cambridge, UK identifies Tia1 as a hair-trigger protein that stop our body’s defences from turning against us.
All cells experience DNA damage but it’s usually minor and can be repaired. The latest research, published in the journal Nature Communications, highlights that standard repair processes are too slow for B cells, where intentional DNA damage is more severe. The results show that B cells plan ahead, priming the DNA repair process early, so when they intentionally damage their own DNA it can be fixed before it causes lasting harm.
As the paper’s first author, Dr Manuel Díaz-Muñoz said: “B cells walk a fine line, some DNA damage is needed for them to make effective antibodies to fight infections, but too much and they become harmful. It’s a tough situation to manage biochemically. Tia1 controls the production of a number of proteins that help cells respond to damaged DNA. Tia1 allows a rapid response from B cells so they can repair DNA damage at a moment’s notice.”
Each illness requires a specific antibody to defeat it. By damaging and repairing the genetic instructions that make antibodies, each B cell produces a unique antibody type and the most effective ones are then used to fight disease. This causes extensive damage to the DNA inside B cells and must be rapidly repaired or genetic mistakes may weaken the immune system or even cause cancer.
Scientists believed that B cells only turn on DNA repair genes when they are needed to repair damage. Yet, these new results completely change this view. These genes are constantly active, but cells only use the information in these genes to make proteins when there is a lot of DNA damage. B cells prepare templates for the proteins but don’t go on to make the proteins themselves.
Tia1 is the protein that enables B cells to stop making DNA repair proteins part way through. When DNA damage is low, Tia1 gathers together the protein templates, called mRNAs, for lots of different DNA repair proteins. When DNA damage increases Tia1 can quickly release all the mRNAs it collected and the cell uses them to make lots of the proteins it needs to fix its genes.
Head of the Lymphocyte Signalling Programme at the Babraham Institute and senior scientist on the paper, Dr Martin Turner, said: “Remarkably, our data suggest that regulation of mRNAs by Tia1 rather than protein destruction controls DNA repair in activated B cells. This is an attractive and little explored mechanism that we are now starting to understand. Controlling protein production in this way is important in other healthy and diseased cells and it will be interesting to see if a similar system exists in other places.”
This article has been republished from materials provided by The Babraham Institute. Note: material may have been edited for length and content. For further information, please contact the cited source.
Díaz-Muñoz, MD., Yu Kiselev, V., Le Novère, N., Curk, T., Ule, J., Turner, M., (2017) 'Tia1 dependent regulation of mRNA subcellular location and translation controls p53 expression in B cells'. Nat Comms 8. http://dx.doi.org/10.1038/s41467-017-00454-2
Working Together Helps Phage Overcome CRISPRNews
Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.READ MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018